shiro888slot| Shanghai Pudong has launched 3 innovative drugs this year, and 16 new drug marketing applications are in the queue

Gelonghui May 22| according to the papershiro888slot, the Pudong New District Biomedical Industry Innovation and Development Conference was held at the Pudong New District Office Center. It was learned from the meeting that three innovative drugs have been approved for marketing in Pudong New District of Shanghai City this year, and 16 new drugs are in the marketing application stage. So far, 24 domestically produced innovative drugs have been approved for marketing in Pudong New District. At the meeting, the biomedical innovations of Pudong New District in 2024 were released, including Kaixing Life's CAR-T cell therapy Zevokiolenza Injection (Cycaze ®), Kezhou Pharmaceutical's first domestic MEK inhibitor Tollamitinib Capsule (Colupin ®), Beida Pharmaceutical's third-generation EGFR inhibitor Rizitinib Mesylate Capsule (Rabida ®), etc.